Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

Hear from 5 experts as they recap some of the top data from this year's AUA.

Take a look through some of the notable studies that were spotlighted during this year’s meeting.

The sBLA for NAI was submitted to the FDA in March 2025.

These results are expected to support submission of the Hugo system to the FDA for use in urologic procedures.

Data showed an overall CR rate of 82.4%.

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.

A recap of the FDA submissions and regulatory decisions in urology from April 2025.

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

The RAPID-III trial will assess outcomes with flexible cystoscopy with or without the FloStent implant deployed.

"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.

Data from the SOUND trial are intended to support submission for FDA 510(k) clearance of the Break Wave device.

View slated interviews with experts as well as insights from urologists on what to watch for.

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.

Take a look through several of the notable phase 3 trials in progress that will be spotlighted at AUA 2025.

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.

We preview several noteworthy P2 presentations in the urologic oncology space.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.

Overall, 71% of patients had no fragment greater than 2 mm following treatment.

There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD.

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC.

Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.

Ian Metzler, MD, discusses developments in imaging and treating stones.

Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.